BTIG Research Lowers Outset Medical (NASDAQ:OM) Price Target to $15.00

Outset Medical (NASDAQ:OM) had its price objective dropped by stock analysts at BTIG Research from $17.00 to $15.00 in a research report issued to clients and investors on Thursday, Marketbeat.com reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price target indicates a potential upside of 342.48% from the company’s current price.

OM has been the topic of several other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a report on Monday, December 29th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $7.00 target price on shares of Outset Medical in a research note on Wednesday, December 17th. Stifel Nicolaus dropped their target price on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 7th. Finally, Wall Street Zen lowered shares of Outset Medical from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Outset Medical Price Performance

NASDAQ OM opened at $3.39 on Thursday. Outset Medical has a fifty-two week low of $3.10 and a fifty-two week high of $21.98. The stock’s 50-day moving average is $4.42 and its two-hundred day moving average is $9.42. The firm has a market cap of $61.53 million, a P/E ratio of -0.50 and a beta of 2.08. The company has a debt-to-equity ratio of 0.69, a current ratio of 7.09 and a quick ratio of 5.77.

Insider Activity at Outset Medical

In related news, General Counsel John L. Brottem sold 9,314 shares of Outset Medical stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $47,687.68. Following the sale, the general counsel directly owned 36,957 shares of the company’s stock, valued at $189,219.84. This trade represents a 20.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Marc Nash sold 5,375 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total value of $27,520.00. Following the completion of the transaction, the executive vice president directly owned 42,785 shares of the company’s stock, valued at approximately $219,059.20. This trade represents a 11.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 35,989 shares of company stock worth $180,073. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of OM. Los Angeles Capital Management LLC bought a new stake in Outset Medical in the 4th quarter valued at $29,000. Legal & General Group Plc acquired a new stake in shares of Outset Medical during the 2nd quarter valued at about $34,000. Ameritas Investment Partners Inc. bought a new stake in Outset Medical in the second quarter valued at about $35,000. BNP Paribas Financial Markets raised its position in Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after purchasing an additional 2,034 shares in the last quarter. Finally, HRT Financial LP acquired a new position in Outset Medical in the fourth quarter worth about $58,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.